# Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

> **NCT02848326** · PHASE2,PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 834 (actual)

## Conditions studied

- Migraine, With or Without Aura

## Interventions

- **DRUG:** Atogepant
- **DRUG:** Placebo-matching Atogepant

## Key facts

- **NCT ID:** NCT02848326
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-06
- **Primary completion:** 2018-04-02
- **Final completion:** 2018-04-23
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2018-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02848326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02848326, "Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02848326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*